Advice
in the absence of a submission from the holder of the marketing authorisation:
alectinib hydrochloride (Alecensa®) is not recommended for use within NHS Scotland.
Indication under review: As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice68KB (PDF)
Medicine details
- Medicine name:
- alectinib hydrochloride (Alecensa)
- SMC ID:
- 1257/17
- Indication:
- As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 May 2017